Swiss pharmaceutical giant Novartis has entered into a license and option agreement with China’s Abogen Biosciences concerning RNA-based medicines.
The agreement includes an exclusive global license to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, as well as options on additional programs from Abogen’s RNA platform, according to a press release.
Abogen will receive 575 million dollars in upfront payment and could, if all options are exercised and milestones are achieved, receive up to approximately 7.2 billion dollars in additional payments. In addition, royalties on future sales may be payable. The transaction is subject to customary regulatory approvals.
